Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 8/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 7/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 7/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | EBP | Q15125 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | GUSB | P08236 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25829707 | 0.92 | GNAO1 (0.40) | GNAO1GNAI3GNAI1KCNH2CHRM3 | |
| SCHEMBL22856209 | 0.88 | GNAO1 (0.45) | GNAO1GNAI3GNAI1KCNH2NPC1 | |
| SCHEMBL25928339 | 0.87 | GNAO1 (0.40) | GNAO1GNAI3GNAI1KCNH2CHRM3 | |
| SCHEMBL25480405 | 0.87 | GNAO1 (0.40) | GNAO1GNAI3GNAI1KCNH2CHRM3 | |
| SCHEMBL25707751 | 0.86 | GNAO1 (0.38) | GNAO1GNAI3GNAI1NPC1BCHE | |
| SCHEMBL23945861 | 0.86 | GNAO1 (0.40) | GNAO1GNAI3GNAI1KCNH2CHRM3 | |
| SCHEMBL25469357 | 0.84 | GNAO1 (0.44) | GNAO1GNAI3GNAI1KCNH2NPC1 | |
| SCHEMBL25833708 | 0.84 | GNAO1 (0.47) | GNAO1GNAI3GNAI1KCNH2EBP | |
| SCHEMBL25123296 | 0.84 | GNAO1 (0.36) | GNAO1GNAI3GNAI1KCNH2NPC1 | |
| SCHEMBL23696802 | 0.83 | GNAO1 (0.35) | GNAO1GNAI3GNAI1NPC1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885GNAI3 1664/4885GNAI1 1458/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | GNAO1 2977/4885GNAI3 1664/4885GNAI1 1458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.